Pharma Focus Europe

Salipro Biotech and Sumitomo Pharma Announce Collaboration to Advance Drug Discovery Program

Wednesday, September 13, 2023

Swedish biotechnology company Salipro Biotech AB has announced a collaborative research effort with Sumitomo Pharma Co., Ltd. The primary objective of this collaboration is to elucidate the mechanism of action and characterize the pharmacological properties of a specific drug candidate.

As part of this partnership, Salipro Biotech will apply its specialized expertise in stabilizing complex membrane proteins, including GPCRs, ion channels, and transporters, using its proprietary Salipro® technology platform. The overarching aim is to support Sumitomo Pharma's drug discovery program by conducting a comprehensive characterization of the drug candidate, tailored to meet specific therapeutic requirements for a chosen target.

Jens Frauenfeld, CEO of Salipro Biotech, expressed excitement about the collaborative endeavor, highlighting the company's distinctive capabilities and the potential to identify previously challenging drug targets. The synergy between Salipro Biotech's expertise and Sumitomo Pharma's advanced capabilities in central nervous system (CNS) drug discovery and development is expected to provide valuable insights into the therapeutic potential of the drug candidate.

Isao Shimizu, Executive Officer, Senior Vice President, Head of Drug Research Division, and Senior Executive Research Director at Sumitomo Pharma, also expressed enthusiasm for the collaboration, emphasizing the opportunity to expedite the understanding of the drug candidate's mechanism of action and its pharmacological characteristics.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva